Biogen Idec and Swedish Orphan Biovitrum Announce Decision to Advance Long-Lasting Hemophilia A Therapy into a Registrational Trial

Friday, July 9, 2010 1 min read

Key Takeaway: Biogen Idec and Swedish Orphan Biovitrum Announce Decision to Advance Long-Lasting Hemophilia A Therapy into a Registrational Trial

Full Press Release Details

Biogen Idec and Swedish Orphan Biovitrum Announce Decision to Advance Long-Lasting Hemophilia A Therapy into a Registrational Trial.